New Therapeutic Uses for Experimental Assets
NCATS matches academic research groups with assets provided by pharmaceutical partners, as part of the New Therapeutic Uses program’s NIH-Industry Partnerships initiative. The goal is to use molecules that have already undergone significant research and development by pharmaceutical companies to more quickly advance new treatments for patients.
Awarded projects support preclinical validation studies, clinical feasibility studies or proof-of-concept clinical trials to test whether the selected assets may be effective against a previously unexplored disease.
Therapeutic/Indication Pairing Strategies
NCATS has released a set of funding opportunities to explore a potential new use of an existing investigational therapy, Food and Drug Administration-approved drug, or licensed biologic. Through the Bench-to-Clinic Repurposing initiative, NCATS will support preclinical studies, clinical feasibility studies or proof-of-concept clinical trials to test the utility of an independent crowdsourcing effort or computational algorithm to predict new uses of a drug or biologic.
- View the 2020 project.
- View the 2019 projects.
- View the 2018 projects.
- View the 2017 projects.
- View the 2016 projects.
Repurposing Off-Patent Drugs Workshop
On Dec. 5, 2019, NCATS hosted Repurposing Off-Patent Drugs: Research & Regulatory Challenges to discuss challenges around finding new uses for drugs that are already on the market but lack commercial and regulatory incentives for research and development.